Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

AbbVie share price

AbbVie Inc. · ABBV · Healthcare · Drug Manufacturers - General · last close in our records 6 November 2026 · results updated weekly · All US stock lists

AbbVie share price: $291.31 at the close on 6 November 2026, the latest close in our records, +32.9% in a year.

MixedBusiness trend from fewer quarters than usual
$291.31Price +32.9% in a year
50.2×P/E lower than 56% of the last 4.6 years
$17.4 BRevenue (Sep 2026) +10.3% on a year ago
$4.2 BProfit (Sep 2026) +2,289.2% on a year ago
39.6%Operating margin +4.1 points on a year ago
−130%ROE FY25
19.7%ROIC against a 5.0% cost of capital: +14.7 points

AbbVie Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers.

The main question: the share price moved +32.9% in a year while yearly earnings per share moved −1.3%. The difference came from the market paying a higher multiple.

The price has been rising for 20 weeks, and the P/E is lower than 56% of its own last 4.6 years. But the balance sheet is under water: net worth is negative, so shareholders come after everyone the company owes. What will decide it: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first.

What is the AbbVie share price?

AbbVie Inc.'s share price was $291.31 at the close on 6 November 2026. It has been rising for 20 weeks. That is 21.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $199 and $295, and at that close it sat 96% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today AbbVie Inc. is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 5 weeks in a row.

1Y

Nov 2026: $291.31, 21.9% above its 200-day average. The price has been rising for 20 weeks.

  • Price $291.31
  • 50-day avg $271.95
  • 200-day avg $238.94
Nov 2026: $291.31, 21.9% above its 200-day average. The price has been rising for 20 weeks.
WeekPrice50-day avg200-day avg
31 Oct 2025$218.04$222.37$199.55
7 Nov 2025$219.16$223.18$200.67
14 Nov 2025$232.36$224.82$202.02
21 Nov 2025$236.28$226.74$203.11
28 Nov 2025$227.70$227.54$203.86
5 Dec 2025$226.08$228.11$204.63
12 Dec 2025$223.32$227.35$205.13
19 Dec 2025$226.82$226.68$205.50
26 Dec 2025$229.98$226.69$205.80
2 Jan 2026$229.31$226.65$206.14
9 Jan 2026$220.08$226.28$206.52
16 Jan 2026$214.35$226.17$206.87
23 Jan 2026$219.26$226.05$207.30
30 Jan 2026$223.01$225.04$208.42
6 Feb 2026$223.43$224.02$209.64
13 Feb 2026$231.50$223.80$210.63
20 Feb 2026$224.81$223.85$211.26
27 Feb 2026$232.08$224.23$212.30
6 Mar 2026$230.11$225.05$213.54
13 Mar 2026$219.68$224.61$214.59
20 Mar 2026$205.07$223.12$215.25
27 Mar 2026$209.40$221.74$215.72
2 Apr 2026$208.84$221.60$216.16
10 Apr 2026$207.94$220.49$216.76
17 Apr 2026$208.38$219.10$217.32
24 Apr 2026$198.71$217.10$217.63
1 May 2026$206.60$214.54$217.93
8 May 2026$201.55$212.32$218.33
15 May 2026$210.39$209.75$218.79
22 May 2026$215.70$208.31$219.23
29 May 2026$217.72$208.23$219.59
5 Jun 2026$227.23$209.61$219.95
12 Jun 2026$227.73$210.80$220.35
18 Jun 2026$216.49$211.77$220.57
26 Jun 2026$253.35$214.78$221.26
2 Jul 2026$261.07$218.62$222.01
10 Jul 2026$248.08$223.92$222.79
17 Jul 2026$254.49$228.11$223.50
24 Jul 2026$259.36$233.29$224.01
31 Jul 2026$250.94$238.07$224.69
7 Aug 2026$246.04$241.15$225.09
14 Aug 2026$249.46$244.46$225.61
21 Aug 2026$264.96$247.99$226.56
28 Aug 2026$255.48$251.77$227.65
4 Sep 2026$256.46$254.48$228.34
11 Sep 2026$257.12$254.51$228.74
18 Sep 2026$263.96$255.35$229.60
25 Sep 2026$264.34$257.05$230.56
2 Oct 2026$262.82$257.84$231.52
9 Oct 2026$276.47$258.89$232.65
16 Oct 2026$285.42$262.45$233.95
23 Oct 2026$285.64$266.12$235.41
30 Oct 2026$294.89$269.29$237.10
6 Nov 2026$291.31$271.95$238.94
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 1-year window.

3Y

Nov 2026: $291.31, 21.9% above its 200-day average. The price has been rising for 20 weeks.

  • Price $291.31
  • 50-day avg $271.95
  • 200-day avg $238.94
Nov 2026: $291.31, 21.9% above its 200-day average. The price has been rising for 20 weeks.
WeekPrice50-day avg200-day avg
3 Nov 2023$141.42$148.22$147.89
10 Nov 2023$138.59$147.52$147.70
17 Nov 2023$138.30$146.58$147.50
24 Nov 2023$138.67$145.60$147.37
1 Dec 2023$143.41$144.30$147.09
8 Dec 2023$149.28$143.61$146.97
15 Dec 2023$154.04$144.17$146.96
22 Dec 2023$154.94$144.62$146.98
29 Dec 2023$154.97$145.13$147.03
5 Jan 2024$162.14$146.35$147.14
12 Jan 2024$162.40$148.40$147.30
19 Jan 2024$164.77$150.06$147.38
26 Jan 2024$164.40$152.61$147.48
2 Feb 2024$168.67$155.39$147.59
9 Feb 2024$174.08$158.89$147.87
16 Feb 2024$177.49$162.13$148.40
23 Feb 2024$178.09$164.35$148.97
1 Mar 2024$178.91$166.76$149.76
8 Mar 2024$178.85$169.35$150.64
15 Mar 2024$177.88$171.64$151.66
22 Mar 2024$178.45$173.20$152.71
28 Mar 2024$182.10$174.61$153.56
5 Apr 2024$170.00$175.64$154.51
12 Apr 2024$162.28$175.96$155.31
19 Apr 2024$166.41$175.24$156.04
26 Apr 2024$159.62$174.49$156.81
3 May 2024$163.79$173.06$157.47
10 May 2024$160.75$171.40$157.95
17 May 2024$166.42$169.82$158.30
24 May 2024$157.06$167.86$158.57
31 May 2024$161.24$166.16$158.67
7 Jun 2024$169.42$164.80$159.05
14 Jun 2024$168.59$163.81$159.57
21 Jun 2024$170.39$163.90$160.04
28 Jun 2024$171.52$164.64$160.60
5 Jul 2024$167.25$164.62$160.89
12 Jul 2024$170.28$165.10$161.26
19 Jul 2024$172.32$165.99$161.76
26 Jul 2024$185.16$167.70$162.51
2 Aug 2024$189.29$169.92$163.47
9 Aug 2024$189.93$172.98$164.48
16 Aug 2024$193.90$176.11$165.70
23 Aug 2024$197.55$178.93$167.07
30 Aug 2024$196.31$181.57$168.48
6 Sep 2024$193.40$183.49$169.62
13 Sep 2024$194.21$186.25$171.05
20 Sep 2024$193.47$188.83$172.36
27 Sep 2024$194.79$191.06$173.49
4 Oct 2024$194.29$193.13$174.54
11 Oct 2024$194.19$193.95$175.56
18 Oct 2024$188.86$194.31$176.41
25 Oct 2024$187.85$193.97$177.05
1 Nov 2024$203.55$194.14$177.93
8 Nov 2024$199.50$194.58$178.81
15 Nov 2024$164.99$192.04$178.93
22 Nov 2024$176.95$189.45$178.87
29 Nov 2024$182.93$188.42$179.01
6 Dec 2024$176.19$186.99$179.06
13 Dec 2024$173.37$184.82$178.98
20 Dec 2024$175.58$182.76$178.83
27 Dec 2024$178.01$181.63$178.81
3 Jan 2025$181.22$180.87$178.80
10 Jan 2025$175.17$180.03$178.81
17 Jan 2025$171.56$177.43$178.64
24 Jan 2025$170.30$175.03$178.63
31 Jan 2025$183.90$175.75$178.91
7 Feb 2025$190.60$177.87$179.56
14 Feb 2025$192.87$178.98$180.24
21 Feb 2025$202.08$180.71$180.98
28 Feb 2025$209.03$183.75$182.07
7 Mar 2025$214.29$187.52$183.26
14 Mar 2025$211.77$191.00$184.58
21 Mar 2025$210.01$194.29$185.95
28 Mar 2025$205.29$197.14$186.87
4 Apr 2025$186.96$200.18$187.72
11 Apr 2025$175.05$200.55$187.89
17 Apr 2025$172.99$199.44$187.99
25 Apr 2025$186.06$198.02$188.26
2 May 2025$198.47$197.86$188.90
9 May 2025$184.60$196.32$189.28
16 May 2025$184.02$193.73$189.33
23 May 2025$183.26$190.73$189.24
30 May 2025$186.11$188.50$189.16
6 Jun 2025$189.83$186.60$189.01
13 Jun 2025$191.08$185.09$188.86
20 Jun 2025$185.30$185.02$188.68
27 Jun 2025$182.31$185.79$188.41
3 Jul 2025$189.28$187.13$188.28
11 Jul 2025$192.45$187.66$188.21
18 Jul 2025$189.26$187.24$188.13
25 Jul 2025$190.28$187.38$187.94
1 Aug 2025$195.22$188.18$187.86
8 Aug 2025$198.05$189.63$188.03
15 Aug 2025$206.69$191.16$188.37
22 Aug 2025$210.60$193.05$188.64
29 Aug 2025$210.40$194.99$188.84
5 Sep 2025$212.56$197.18$189.66
12 Sep 2025$218.34$199.88$190.82
19 Sep 2025$222.47$202.82$191.81
26 Sep 2025$220.61$205.86$192.87
3 Oct 2025$233.91$210.39$194.36
10 Oct 2025$230.50$214.54$195.80
17 Oct 2025$229.57$217.66$197.05
24 Oct 2025$227.99$220.59$198.30
31 Oct 2025$218.04$222.37$199.55
7 Nov 2025$219.16$223.18$200.67
14 Nov 2025$232.36$224.82$202.02
21 Nov 2025$236.28$226.74$203.11
28 Nov 2025$227.70$227.54$203.86
5 Dec 2025$226.08$228.11$204.63
12 Dec 2025$223.32$227.35$205.13
19 Dec 2025$226.82$226.68$205.50
26 Dec 2025$229.98$226.69$205.80
2 Jan 2026$229.31$226.65$206.14
9 Jan 2026$220.08$226.28$206.52
16 Jan 2026$214.35$226.17$206.87
23 Jan 2026$219.26$226.05$207.30
30 Jan 2026$223.01$225.04$208.42
6 Feb 2026$223.43$224.02$209.64
13 Feb 2026$231.50$223.80$210.63
20 Feb 2026$224.81$223.85$211.26
27 Feb 2026$232.08$224.23$212.30
6 Mar 2026$230.11$225.05$213.54
13 Mar 2026$219.68$224.61$214.59
20 Mar 2026$205.07$223.12$215.25
27 Mar 2026$209.40$221.74$215.72
2 Apr 2026$208.84$221.60$216.16
10 Apr 2026$207.94$220.49$216.76
17 Apr 2026$208.38$219.10$217.32
24 Apr 2026$198.71$217.10$217.63
1 May 2026$206.60$214.54$217.93
8 May 2026$201.55$212.32$218.33
15 May 2026$210.39$209.75$218.79
22 May 2026$215.70$208.31$219.23
29 May 2026$217.72$208.23$219.59
5 Jun 2026$227.23$209.61$219.95
12 Jun 2026$227.73$210.80$220.35
18 Jun 2026$216.49$211.77$220.57
26 Jun 2026$253.35$214.78$221.26
2 Jul 2026$261.07$218.62$222.01
10 Jul 2026$248.08$223.92$222.79
17 Jul 2026$254.49$228.11$223.50
24 Jul 2026$259.36$233.29$224.01
31 Jul 2026$250.94$238.07$224.69
7 Aug 2026$246.04$241.15$225.09
14 Aug 2026$249.46$244.46$225.61
21 Aug 2026$264.96$247.99$226.56
28 Aug 2026$255.48$251.77$227.65
4 Sep 2026$256.46$254.48$228.34
11 Sep 2026$257.12$254.51$228.74
18 Sep 2026$263.96$255.35$229.60
25 Sep 2026$264.34$257.05$230.56
2 Oct 2026$262.82$257.84$231.52
9 Oct 2026$276.47$258.89$232.65
16 Oct 2026$285.42$262.45$233.95
23 Oct 2026$285.64$266.12$235.41
30 Oct 2026$294.89$269.29$237.10
6 Nov 2026$291.31$271.95$238.94
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 3-year window.

5Y

Nov 2026: $291.31, 21.9% above its 200-day average. The price has been rising for 20 weeks.

  • Price $291.31
  • 50-day avg $271.95
  • 200-day avg $238.94
Nov 2026: $291.31, 21.9% above its 200-day average. The price has been rising for 20 weeks.
WeekPrice50-day avg200-day avg
5 Nov 2021$117.18$110.27$111.40
19 Nov 2021$116.24$110.98$111.94
3 Dec 2021$118.85$112.75$112.48
17 Dec 2021$129.53$116.22$113.41
31 Dec 2021$135.40$120.65$114.59
14 Jan 2022$135.87$125.43$116.08
28 Jan 2022$137.92$128.65$117.34
11 Feb 2022$142.01$133.43$118.86
25 Feb 2022$149.54$137.55$120.24
11 Mar 2022$149.06$140.91$121.88
25 Mar 2022$161.33$145.38$124.14
8 Apr 2022$174.96$151.65$126.68
22 Apr 2022$154.99$155.31$128.75
6 May 2022$152.83$156.96$130.54
20 May 2022$151.01$157.72$132.33
3 Jun 2022$147.17$156.27$133.79
17 Jun 2022$138.28$152.22$134.97
1 Jul 2022$153.80$149.83$136.88
15 Jul 2022$153.62$149.61$138.92
29 Jul 2022$143.51$148.79$140.89
12 Aug 2022$142.60$146.93$142.49
26 Aug 2022$136.35$146.13$143.76
9 Sep 2022$141.42$144.30$144.70
23 Sep 2022$143.06$142.12$145.89
7 Oct 2022$138.76$140.29$146.54
21 Oct 2022$147.06$140.73$146.94
4 Nov 2022$145.28$142.19$147.57
18 Nov 2022$154.98$144.85$148.32
2 Dec 2022$163.66$148.14$149.07
16 Dec 2022$160.48$152.72$149.92
30 Dec 2022$161.61$156.39$150.43
13 Jan 2023$153.60$158.44$150.42
27 Jan 2023$146.28$158.60$149.61
10 Feb 2023$152.05$156.62$149.00
24 Feb 2023$152.71$154.46$149.00
10 Mar 2023$149.71$152.50$149.02
24 Mar 2023$158.02$151.06$149.34
6 Apr 2023$161.55$152.73$150.14
21 Apr 2023$162.41$155.87$150.60
5 May 2023$148.03$156.41$150.74
19 May 2023$145.11$154.90$150.70
2 Jun 2023$136.87$152.18$150.61
16 Jun 2023$138.64$147.90$150.52
30 Jun 2023$134.73$143.16$150.36
14 Jul 2023$136.01$139.16$150.07
28 Jul 2023$150.85$138.21$150.16
11 Aug 2023$152.18$139.96$150.45
25 Aug 2023$146.69$142.51$150.53
8 Sep 2023$149.02$144.62$150.37
22 Sep 2023$152.74$148.03$149.96
6 Oct 2023$148.24$149.94$149.28
20 Oct 2023$146.23$149.62$148.57
3 Nov 2023$141.42$148.22$147.89
17 Nov 2023$138.30$146.58$147.50
1 Dec 2023$143.41$144.30$147.09
15 Dec 2023$154.04$144.17$146.96
29 Dec 2023$154.97$145.13$147.03
12 Jan 2024$162.40$148.40$147.30
26 Jan 2024$164.40$152.61$147.48
9 Feb 2024$174.08$158.89$147.87
23 Feb 2024$178.09$164.35$148.97
8 Mar 2024$178.85$169.35$150.64
22 Mar 2024$178.45$173.20$152.71
5 Apr 2024$170.00$175.64$154.51
19 Apr 2024$166.41$175.24$156.04
3 May 2024$163.79$173.06$157.47
17 May 2024$166.42$169.82$158.30
31 May 2024$161.24$166.16$158.67
14 Jun 2024$168.59$163.81$159.57
28 Jun 2024$171.52$164.64$160.60
12 Jul 2024$170.28$165.10$161.26
26 Jul 2024$185.16$167.70$162.51
9 Aug 2024$189.93$172.98$164.48
23 Aug 2024$197.55$178.93$167.07
6 Sep 2024$193.40$183.49$169.62
20 Sep 2024$193.47$188.83$172.36
4 Oct 2024$194.29$193.13$174.54
18 Oct 2024$188.86$194.31$176.41
1 Nov 2024$203.55$194.14$177.93
15 Nov 2024$164.99$192.04$178.93
29 Nov 2024$182.93$188.42$179.01
13 Dec 2024$173.37$184.82$178.98
27 Dec 2024$178.01$181.63$178.81
10 Jan 2025$175.17$180.03$178.81
24 Jan 2025$170.30$175.03$178.63
7 Feb 2025$190.60$177.87$179.56
21 Feb 2025$202.08$180.71$180.98
7 Mar 2025$214.29$187.52$183.26
21 Mar 2025$210.01$194.29$185.95
4 Apr 2025$186.96$200.18$187.72
17 Apr 2025$172.99$199.44$187.99
2 May 2025$198.47$197.86$188.90
16 May 2025$184.02$193.73$189.33
30 May 2025$186.11$188.50$189.16
13 Jun 2025$191.08$185.09$188.86
27 Jun 2025$182.31$185.79$188.41
11 Jul 2025$192.45$187.66$188.21
25 Jul 2025$190.28$187.38$187.94
8 Aug 2025$198.05$189.63$188.03
22 Aug 2025$210.60$193.05$188.64
5 Sep 2025$212.56$197.18$189.66
19 Sep 2025$222.47$202.82$191.81
3 Oct 2025$233.91$210.39$194.36
17 Oct 2025$229.57$217.66$197.05
31 Oct 2025$218.04$222.37$199.55
14 Nov 2025$232.36$224.82$202.02
28 Nov 2025$227.70$227.54$203.86
12 Dec 2025$223.32$227.35$205.13
26 Dec 2025$229.98$226.69$205.80
9 Jan 2026$220.08$226.28$206.52
23 Jan 2026$219.26$226.05$207.30
6 Feb 2026$223.43$224.02$209.64
20 Feb 2026$224.81$223.85$211.26
6 Mar 2026$230.11$225.05$213.54
20 Mar 2026$205.07$223.12$215.25
2 Apr 2026$208.84$221.60$216.16
17 Apr 2026$208.38$219.10$217.32
1 May 2026$206.60$214.54$217.93
15 May 2026$210.39$209.75$218.79
29 May 2026$217.72$208.23$219.59
12 Jun 2026$227.73$210.80$220.35
26 Jun 2026$253.35$214.78$221.26
10 Jul 2026$248.08$223.92$222.79
24 Jul 2026$259.36$233.29$224.01
7 Aug 2026$246.04$241.15$225.09
21 Aug 2026$264.96$247.99$226.56
4 Sep 2026$256.46$254.48$228.34
18 Sep 2026$263.96$255.35$229.60
2 Oct 2026$262.82$257.84$231.52
16 Oct 2026$285.42$262.45$233.95
30 Oct 2026$294.89$269.29$237.10
6 Nov 2026$291.31$271.95$238.94
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 5-year window.

10Y

Nov 2026: $291.31, 21.9% above its 200-day average. The price has been rising for 20 weeks.

  • Price $291.31
  • 50-day avg $271.95
  • 200-day avg $238.94
Nov 2026: $291.31, 21.9% above its 200-day average. The price has been rising for 20 weeks.
WeekPrice50-day avg200-day avg
4 Nov 2016$56.04$62.24–
25 Nov 2016$60.51$61.45–
16 Dec 2016$62.22$60.66–
6 Jan 2017$63.79$60.93–
27 Jan 2017$60.00$61.56–
17 Feb 2017$61.77$61.63–
10 Mar 2017$65.88$61.99–
31 Mar 2017$65.16$62.94–
21 Apr 2017$63.82$63.97$63.00
12 May 2017$66.06$65.28$63.15
2 Jun 2017$67.25$65.57$63.12
23 Jun 2017$72.64$67.06$63.50
14 Jul 2017$73.11$69.13$64.09
4 Aug 2017$70.99$70.91$64.82
25 Aug 2017$72.48$71.80$65.72
15 Sep 2017$87.37$74.21$67.07
6 Oct 2017$90.49$78.79$69.08
27 Oct 2017$91.93$85.33$71.32
17 Nov 2017$93.61$90.99$73.75
8 Dec 2017$95.95$93.25$76.13
29 Dec 2017$96.71$95.02$78.45
19 Jan 2018$104.64$97.25$80.76
9 Feb 2018$111.30$102.52$84.35
2 Mar 2018$115.04$108.14$87.84
23 Mar 2018$97.46$112.53$91.35
13 Apr 2018$91.83$108.14$92.85
4 May 2018$100.17$102.72$94.62
25 May 2018$101.08$98.71$97.01
15 Jun 2018$99.57$98.75$98.98
6 Jul 2018$96.92$99.35$99.82
27 Jul 2018$90.56$97.12$100.20
17 Aug 2018$98.81$95.16$100.43
7 Sep 2018$94.17$95.06$100.61
28 Sep 2018$94.58$94.74$100.48
19 Oct 2018$87.97$94.57$100.08
9 Nov 2018$88.79$90.16$98.46
30 Nov 2018$94.27$88.69$96.74
21 Dec 2018$84.92$86.76$94.66
11 Jan 2019$88.31$87.42$93.32
1 Feb 2019$80.50$86.90$92.70
22 Feb 2019$80.02$84.33$91.53
15 Mar 2019$81.34$81.95$89.70
5 Apr 2019$83.45$79.96$88.34
26 Apr 2019$79.70$80.20$87.34
17 May 2019$79.46$79.89$86.26
7 Jun 2019$77.43$79.49$85.02
28 Jun 2019$72.72$77.74$83.51
19 Jul 2019$68.54$75.60$81.92
9 Aug 2019$65.58$71.79$80.00
30 Aug 2019$65.74$68.18$78.70
20 Sep 2019$72.39$67.29$77.31
11 Oct 2019$73.63$69.02$76.33
1 Nov 2019$81.75$72.60$75.49
22 Nov 2019$86.05$78.17$75.81
13 Dec 2019$87.84$82.22$76.31
3 Jan 2020$88.70$85.97$76.96
24 Jan 2020$83.54$88.08$77.43
14 Feb 2020$94.05$88.35$78.07
6 Mar 2020$88.82$88.99$78.90
27 Mar 2020$72.67$84.76$78.67
17 Apr 2020$83.45$82.84$78.88
8 May 2020$83.96$80.01$79.86
29 May 2020$92.67$81.95$81.61
19 Jun 2020$96.71$88.36$83.72
10 Jul 2020$96.83$92.67$85.64
31 Jul 2020$94.91$95.91$87.45
21 Aug 2020$94.86$96.50$88.66
11 Sep 2020$89.70$95.53$89.10
2 Oct 2020$86.12$92.35$89.15
23 Oct 2020$84.34$89.68$88.90
13 Nov 2020$99.04$88.49$89.24
4 Dec 2020$107.28$92.15$89.99
24 Dec 2020$103.26$97.17$91.22
15 Jan 2021$110.52$103.66$93.67
5 Feb 2021$108.73$106.40$95.63
26 Feb 2021$107.74$106.48$97.14
19 Mar 2021$103.42$107.24$98.35
9 Apr 2021$107.54$106.19$99.11
30 Apr 2021$111.50$107.52$99.98
21 May 2021$116.12$110.17$101.39
11 Jun 2021$115.42$112.23$102.73
2 Jul 2021$115.17$114.20$104.39
23 Jul 2021$118.19$115.13$106.45
13 Aug 2021$116.48$115.49$108.74
3 Sep 2021$111.62$116.54$110.63
24 Sep 2021$107.07$114.33$110.89
15 Oct 2021$109.33$111.99$111.22
5 Nov 2021$117.18$110.27$111.40
26 Nov 2021$116.51$111.78$112.19
17 Dec 2021$129.53$116.22$113.41
7 Jan 2022$134.88$123.29$115.36
28 Jan 2022$137.92$128.65$117.34
18 Feb 2022$144.03$135.88$119.61
11 Mar 2022$149.06$140.91$121.88
1 Apr 2022$162.68$148.14$125.32
22 Apr 2022$154.99$155.31$128.75
13 May 2022$153.50$157.32$131.40
3 Jun 2022$147.17$156.27$133.79
24 Jun 2022$152.34$150.37$135.72
15 Jul 2022$153.62$149.61$138.92
5 Aug 2022$138.04$147.72$141.68
26 Aug 2022$136.35$146.13$143.76
16 Sep 2022$144.06$143.13$145.31
7 Oct 2022$138.76$140.29$146.54
28 Oct 2022$147.61$141.61$147.31
18 Nov 2022$154.98$144.85$148.32
9 Dec 2022$163.06$150.31$149.55
30 Dec 2022$161.61$156.39$150.43
20 Jan 2023$149.59$158.81$150.17
10 Feb 2023$152.05$156.62$149.00
3 Mar 2023$156.06$153.64$149.03
24 Mar 2023$158.02$151.06$149.34
14 Apr 2023$161.59$154.24$150.41
5 May 2023$148.03$156.41$150.74
26 May 2023$137.56$153.70$150.73
16 Jun 2023$138.64$147.90$150.52
7 Jul 2023$135.50$141.01$150.24
28 Jul 2023$150.85$138.21$150.16
18 Aug 2023$150.14$141.50$150.48
8 Sep 2023$149.02$144.62$150.37
29 Sep 2023$149.06$149.54$149.66
20 Oct 2023$146.23$149.62$148.57
10 Nov 2023$138.59$147.52$147.70
1 Dec 2023$143.41$144.30$147.09
22 Dec 2023$154.94$144.62$146.98
12 Jan 2024$162.40$148.40$147.30
2 Feb 2024$168.67$155.39$147.59
23 Feb 2024$178.09$164.35$148.97
15 Mar 2024$177.88$171.64$151.66
5 Apr 2024$170.00$175.64$154.51
26 Apr 2024$159.62$174.49$156.81
17 May 2024$166.42$169.82$158.30
7 Jun 2024$169.42$164.80$159.05
28 Jun 2024$171.52$164.64$160.60
19 Jul 2024$172.32$165.99$161.76
9 Aug 2024$189.93$172.98$164.48
30 Aug 2024$196.31$181.57$168.48
20 Sep 2024$193.47$188.83$172.36
11 Oct 2024$194.19$193.95$175.56
1 Nov 2024$203.55$194.14$177.93
22 Nov 2024$176.95$189.45$178.87
13 Dec 2024$173.37$184.82$178.98
3 Jan 2025$181.22$180.87$178.80
24 Jan 2025$170.30$175.03$178.63
14 Feb 2025$192.87$178.98$180.24
7 Mar 2025$214.29$187.52$183.26
28 Mar 2025$205.29$197.14$186.87
17 Apr 2025$172.99$199.44$187.99
9 May 2025$184.60$196.32$189.28
30 May 2025$186.11$188.50$189.16
20 Jun 2025$185.30$185.02$188.68
11 Jul 2025$192.45$187.66$188.21
1 Aug 2025$195.22$188.18$187.86
22 Aug 2025$210.60$193.05$188.64
12 Sep 2025$218.34$199.88$190.82
3 Oct 2025$233.91$210.39$194.36
24 Oct 2025$227.99$220.59$198.30
14 Nov 2025$232.36$224.82$202.02
5 Dec 2025$226.08$228.11$204.63
26 Dec 2025$229.98$226.69$205.80
16 Jan 2026$214.35$226.17$206.87
6 Feb 2026$223.43$224.02$209.64
27 Feb 2026$232.08$224.23$212.30
20 Mar 2026$205.07$223.12$215.25
10 Apr 2026$207.94$220.49$216.76
1 May 2026$206.60$214.54$217.93
22 May 2026$215.70$208.31$219.23
12 Jun 2026$227.73$210.80$220.35
2 Jul 2026$261.07$218.62$222.01
24 Jul 2026$259.36$233.29$224.01
14 Aug 2026$249.46$244.46$225.61
4 Sep 2026$256.46$254.48$228.34
25 Sep 2026$264.34$257.05$230.56
16 Oct 2026$285.42$262.45$233.95
6 Nov 2026$291.31$271.95$238.94
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 10-year window.

Price stage: Rising from Oct 2025 to Mar 2026; Sideways from Mar 2026 to Jun 2026; Rising from Jun 2026 to Nov 2026.

Price stage: Falling from Nov 2023 to Dec 2023; Sideways from Dec 2023 to Mar 2024; Rising from Mar 2024 to Nov 2024; Sideways from Dec 2024 to Jan 2025; Rising from Jan 2025 to Mar 2025; Sideways from Apr 2025 to Jun 2025; Rising from Jul 2025 to Mar 2026; Sideways from Mar 2026 to Jun 2026; Rising from Jun 2026 to Nov 2026.

Price stage: Rising from Nov 2021 to Aug 2022; Sideways from Aug 2022 to Nov 2022; Rising from Nov 2022 to Apr 2023; Sideways from May 2023 to Oct 2023; Falling from Nov 2023 to Dec 2023; Sideways from Dec 2023 to Mar 2024; Rising from Mar 2024 to Nov 2024; Sideways from Dec 2024 to Jan 2025; Rising from Feb 2025 to Mar 2026; Sideways from Mar 2026 to May 2026; Rising from Jun 2026 to Nov 2026.

Price stage: Rising from Nov 2017 to Jun 2018; Sideways from Jul 2018 to Nov 2018; Falling from Dec 2018 to Oct 2019; Sideways from Nov 2019 to Mar 2020; Rising from Apr 2020 to Jul 2022; Sideways from Aug 2022 to Oct 2022; Rising from Oct 2022 to Apr 2023; Sideways from May 2023 to Dec 2023; Sideways from Dec 2023 to Mar 2024; Rising from Apr 2024 to Mar 2025; Sideways from Apr 2025 to Jun 2025; Rising from Jul 2025 to Feb 2026; Sideways from Mar 2026 to May 2026; Rising from Jun 2026 to Nov 2026.

Week by week since 2016: did it beat the S&P 500 over the past 13 weeks?

Ahead in 257 of 527 weeks

Week by week since 2016: did it beat the S&P 500 over the past 13 weeks?
Week13-week return vs S&P 500
8 Jul 2016no S&P 500 reading
15 Jul 2016no S&P 500 reading
22 Jul 2016no S&P 500 reading
29 Jul 2016no S&P 500 reading
5 Aug 2016no S&P 500 reading
12 Aug 2016no S&P 500 reading
19 Aug 2016no S&P 500 reading
26 Aug 2016no S&P 500 reading
2 Sep 2016no S&P 500 reading
9 Sep 2016no S&P 500 reading
16 Sep 2016no S&P 500 reading
23 Sep 2016no S&P 500 reading
30 Sep 2016no S&P 500 reading
7 Oct 2016−3.0%
14 Oct 2016−3.7%
21 Oct 2016−2.9%
28 Oct 2016−10.9%
4 Nov 2016−11.4%
11 Nov 2016−5.2%
18 Nov 2016−9.8%
25 Nov 2016−8.3%
2 Dec 2016−7.9%
9 Dec 2016−9.1%
16 Dec 2016−7.1%
23 Dec 2016−8.6%
30 Dec 2016−4.1%
6 Jan 2017−4.3%
13 Jan 2017−3.5%
20 Jan 2017−5.7%
27 Jan 2017−3.6%
3 Feb 2017−1.7%
10 Feb 2017−11.2%
17 Feb 2017−5.5%
24 Feb 2017−4.3%
3 Mar 2017−2.0%
10 Mar 2017+2.1%
17 Mar 2017+0.2%
24 Mar 2017+1.7%
31 Mar 2017−1.4%
7 Apr 2017−0.8%
13 Apr 2017+1.0%
21 Apr 2017+0.9%
28 Apr 2017+5.9%
5 May 2017+5.9%
12 May 2017+6.1%
19 May 2017+4.8%
26 May 2017+4.3%
2 Jun 2017+3.8%
9 Jun 2017+3.3%
16 Jun 2017+5.8%
23 Jun 2017+6.7%
30 Jun 2017+8.7%
7 Jul 2017+7.0%
14 Jul 2017+8.4%
21 Jul 2017+11.7%
28 Jul 2017+3.1%
4 Aug 2017+2.8%
11 Aug 2017+4.8%
18 Aug 2017+4.8%
25 Aug 2017+8.5%
1 Sep 2017+10.6%
8 Sep 2017+21.2%
15 Sep 2017+20.3%
22 Sep 2017+17.8%
29 Sep 2017+18.6%
6 Oct 2017+20.6%
13 Oct 2017+20.2%
20 Oct 2017+24.6%
27 Oct 2017+26.1%
3 Nov 2017+25.6%
10 Nov 2017+29.4%
17 Nov 2017+27.6%
24 Nov 2017+24.2%
1 Dec 2017+21.0%
8 Dec 2017+4.8%
15 Dec 2017+4.6%
22 Dec 2017+5.0%
29 Dec 2017+2.6%
5 Jan 2018+4.2%
12 Jan 2018+1.7%
19 Jan 2018−0.2%
26 Jan 2018+22.8%
2 Feb 2018+18.2%
9 Feb 2018+15.3%
16 Feb 2018+20.8%
23 Feb 2018+19.9%
2 Mar 2018+17.7%
9 Mar 2018+19.3%
16 Mar 2018+13.8%
23 Mar 2018+2.8%
29 Mar 2018−0.7%
6 Apr 2018−6.2%
13 Apr 2018−3.9%
20 Apr 2018−6.6%
27 Apr 2018−12.9%
4 May 2018−9.6%
11 May 2018−10.7%
18 May 2018−10.0%
25 May 2018−13.9%
1 Jun 2018−16.4%
8 Jun 2018−15.6%
15 Jun 2018−13.5%
22 Jun 2018−10.5%
29 Jun 2018−5.2%
6 Jul 2018+1.9%
13 Jul 2018−0.2%
20 Jul 2018−8.9%
27 Jul 2018−13.8%
3 Aug 2018−10.2%
10 Aug 2018−11.8%
17 Aug 2018−11.8%
24 Aug 2018−9.3%
31 Aug 2018−8.2%
7 Sep 2018−9.6%
14 Sep 2018−8.9%
21 Sep 2018−7.6%
28 Sep 2018−5.1%
5 Oct 2018−7.1%
12 Oct 2018−4.8%
19 Oct 2018+0.2%
26 Oct 2018−5.1%
2 Nov 2018−13.5%
9 Nov 2018−5.4%
16 Nov 2018−3.4%
23 Nov 2018−3.6%
30 Nov 2018+3.3%
7 Dec 2018+0.7%
14 Dec 2018−0.1%
21 Dec 2018+9.6%
28 Dec 2018+11.1%
4 Jan 2019+6.7%
11 Jan 2019+3.5%
18 Jan 2019+5.3%
25 Jan 2019−0.5%
1 Feb 2019+1.9%
8 Feb 2019−7.6%
15 Feb 2019−13.0%
22 Feb 2019−12.6%
1 Mar 2019−16.8%
8 Mar 2019−14.9%
15 Mar 2019−13.0%
22 Mar 2019−22.1%
29 Mar 2019−25.6%
5 Apr 2019−20.6%
12 Apr 2019−20.6%
18 Apr 2019−22.2%
26 Apr 2019−11.4%
3 May 2019−11.1%
10 May 2019−9.3%
17 May 2019−4.8%
24 May 2019−1.3%
31 May 2019−2.4%
7 Jun 2019−5.0%
14 Jun 2019−6.1%
21 Jun 2019−6.5%
28 Jun 2019−13.5%
5 Jul 2019−16.0%
12 Jul 2019−16.6%
19 Jul 2019−14.1%
26 Jul 2019−17.9%
2 Aug 2019−16.5%
9 Aug 2019−16.5%
16 Aug 2019−20.0%
23 Aug 2019−18.3%
30 Aug 2019−20.5%
6 Sep 2019−16.3%
13 Sep 2019−14.5%
20 Sep 2019−9.6%
27 Sep 2019+2.1%
4 Oct 2019+3.7%
11 Oct 2019+6.2%
18 Oct 2019+11.3%
25 Oct 2019+13.1%
1 Nov 2019+20.5%
8 Nov 2019+24.0%
15 Nov 2019+29.6%
22 Nov 2019+21.3%
29 Nov 2019+26.0%
6 Dec 2019+23.0%
13 Dec 2019+19.2%
20 Dec 2019+15.8%
27 Dec 2019+9.9%
3 Jan 2020+9.3%
10 Jan 2020+11.0%
17 Jan 2020+3.7%
24 Jan 2020+0.2%
31 Jan 2020−6.0%
7 Feb 2020+0.8%
14 Feb 2020−2.2%
21 Feb 2020+3.1%
28 Feb 2020+3.4%
6 Mar 2020+7.6%
13 Mar 2020+12.3%
20 Mar 2020+5.7%
27 Mar 2020+3.0%
3 Apr 2020+5.7%
9 Apr 2020+4.1%
17 Apr 2020+8.5%
24 Apr 2020+14.0%
1 May 2020+14.3%
8 May 2020+2.9%
15 May 2020+11.7%
22 May 2020+8.4%
29 May 2020+5.4%
5 Jun 2020−1.7%
12 Jun 2020−4.6%
19 Jun 2020+5.6%
26 Jun 2020+13.9%
2 Jul 2020+9.0%
10 Jul 2020+7.3%
17 Jul 2020+8.6%
24 Jul 2020+2.8%
31 Jul 2020−0.9%
7 Aug 2020−3.7%
14 Aug 2020−12.9%
21 Aug 2020−11.9%
28 Aug 2020−13.6%
4 Sep 2020−9.4%
11 Sep 2020−12.8%
18 Sep 2020−14.0%
25 Sep 2020−19.9%
2 Oct 2020−19.8%
9 Oct 2020−18.6%
16 Oct 2020−22.4%
23 Oct 2020−20.9%
30 Oct 2020−10.3%
6 Nov 2020−4.7%
13 Nov 2020−2.1%
20 Nov 2020+1.6%
27 Nov 2020+7.6%
4 Dec 2020+8.8%
11 Dec 2020+8.9%
18 Dec 2020+4.3%
24 Dec 2020+7.5%
31 Dec 2020+12.4%
8 Jan 2021+12.4%
15 Jan 2021+19.9%
22 Jan 2021+20.7%
29 Jan 2021+7.1%
5 Feb 2021+6.4%
12 Feb 2021−4.2%
19 Feb 2021−5.6%
26 Feb 2021−1.9%
5 Mar 2021−4.3%
12 Mar 2021−5.8%
19 Mar 2021−6.5%
26 Mar 2021−4.7%
1 Apr 2021−5.9%
9 Apr 2021−7.7%
16 Apr 2021−13.4%
23 Apr 2021−8.4%
30 Apr 2021−4.0%
7 May 2021−2.4%
14 May 2021+5.4%
21 May 2021+4.2%
28 May 2021−5.4%
4 Jun 2021−4.9%
11 Jun 2021−1.0%
18 Jun 2021+2.8%
25 Jun 2021−1.1%
2 Jul 2021−2.1%
9 Jul 2021+2.6%
16 Jul 2021+5.5%
23 Jul 2021+0.5%
30 Jul 2021−0.8%
6 Aug 2021−5.9%
13 Aug 2021−7.0%
20 Aug 2021−4.5%
27 Aug 2021−1.6%
3 Sep 2021−7.9%
10 Sep 2021−12.6%
17 Sep 2021−11.1%
24 Sep 2021−9.3%
1 Oct 2021−5.4%
8 Oct 2021−5.2%
15 Oct 2021−10.3%
22 Oct 2021−10.7%
29 Oct 2021−6.1%
5 Nov 2021−3.5%
12 Nov 2021−4.4%
19 Nov 2021−7.9%
26 Nov 2021−4.5%
3 Dec 2021+6.4%
10 Dec 2021+11.9%
17 Dec 2021+16.1%
23 Dec 2021+18.3%
31 Dec 2021+14.7%
7 Jan 2022+14.9%
14 Jan 2022+20.0%
21 Jan 2022+24.3%
28 Jan 2022+24.0%
4 Feb 2022+24.3%
11 Feb 2022+27.1%
18 Feb 2022+31.3%
25 Feb 2022+33.0%
4 Mar 2022+31.4%
11 Mar 2022+29.6%
18 Mar 2022+26.2%
25 Mar 2022+25.0%
1 Apr 2022+24.8%
8 Apr 2022+33.7%
14 Apr 2022+25.3%
22 Apr 2022+20.2%
29 Apr 2022+13.3%
6 May 2022+17.0%
13 May 2022+16.9%
20 May 2022+15.1%
27 May 2022+5.4%
3 Jun 2022+2.8%
10 Jun 2022+3.3%
17 Jun 2022+4.6%
24 Jun 2022+8.3%
1 Jul 2022+10.4%
8 Jul 2022+0.5%
15 Jul 2022+6.7%
22 Jul 2022+3.1%
29 Jul 2022−2.3%
5 Aug 2022−10.2%
12 Aug 2022−13.4%
19 Aug 2022−14.4%
26 Aug 2022−6.7%
2 Sep 2022−2.9%
9 Sep 2022−5.6%
16 Sep 2022−1.2%
23 Sep 2022−0.4%
30 Sep 2022−6.4%
7 Oct 2022−2.6%
14 Oct 2022+0.2%
21 Oct 2022+4.3%
28 Oct 2022+8.4%
4 Nov 2022+14.2%
11 Nov 2022+12.0%
18 Nov 2022+15.4%
25 Nov 2022+17.8%
2 Dec 2022+16.4%
9 Dec 2022+18.6%
16 Dec 2022+12.0%
23 Dec 2022+9.9%
30 Dec 2022+13.3%
6 Jan 2023+13.1%
13 Jan 2023−4.0%
20 Jan 2023−4.0%
27 Jan 2023−5.2%
3 Feb 2023−9.6%
10 Feb 2023−1.1%
17 Feb 2023−5.2%
24 Feb 2023−2.9%
3 Mar 2023−4.0%
10 Mar 2023−6.3%
17 Mar 2023−5.7%
24 Mar 2023−6.5%
31 Mar 2023−8.4%
6 Apr 2023−8.4%
14 Apr 2023+1.7%
21 Apr 2023+4.4%
28 Apr 2023+0.8%
5 May 2023+1.9%
12 May 2023−4.1%
19 May 2023−6.9%
26 May 2023−15.9%
2 Jun 2023−18.2%
9 Jun 2023−19.1%
16 Jun 2023−22.8%
23 Jun 2023−23.5%
30 Jun 2023−23.7%
7 Jul 2023−23.3%
14 Jul 2023−24.8%
21 Jul 2023−21.2%
28 Jul 2023−10.0%
4 Aug 2023−8.5%
11 Aug 2023−4.9%
18 Aug 2023−0.8%
25 Aug 2023+1.9%
1 Sep 2023+2.8%
8 Sep 2023+4.2%
15 Sep 2023+8.8%
22 Sep 2023+13.0%
29 Sep 2023+14.2%
6 Oct 2023+11.5%
13 Oct 2023+12.7%
20 Oct 2023+8.6%
27 Oct 2023+2.2%
3 Nov 2023−1.6%
10 Nov 2023−7.8%
17 Nov 2023−11.2%
24 Nov 2023−9.0%
1 Dec 2023−5.0%
8 Dec 2023−3.1%
15 Dec 2023−4.6%
22 Dec 2023−8.6%
29 Dec 2023−7.2%
5 Jan 2024+0.4%
12 Jan 2024−0.7%
19 Jan 2024−1.9%
26 Jan 2024−0.4%
2 Feb 2024+5.5%
9 Feb 2024+11.9%
16 Feb 2024+17.5%
23 Feb 2024+16.9%
1 Mar 2024+13.0%
8 Mar 2024+8.6%
15 Mar 2024+6.8%
22 Mar 2024+5.1%
28 Mar 2024+7.5%
5 Apr 2024−5.9%
12 Apr 2024−7.2%
19 Apr 2024−1.6%
26 Apr 2024−7.2%
3 May 2024−6.3%
10 May 2024−11.6%
17 May 2024−12.2%
24 May 2024−16.1%
31 May 2024−12.7%
7 Jun 2024−9.6%
14 Jun 2024−11.7%
21 Jun 2024−9.0%
28 Jun 2024−9.9%
5 Jul 2024−8.6%
12 Jul 2024−4.7%
19 Jul 2024−7.3%
26 Jul 2024+8.9%
2 Aug 2024+11.3%
9 Aug 2024+15.8%
16 Aug 2024+11.8%
23 Aug 2024+19.6%
30 Aug 2024+14.9%
6 Sep 2024+13.0%
13 Sep 2024+11.7%
20 Sep 2024+9.2%
27 Sep 2024+8.6%
4 Oct 2024+12.9%
11 Oct 2024+10.5%
18 Oct 2024+3.1%
25 Oct 2024−4.9%
1 Nov 2024+0.4%
8 Nov 2024−7.2%
15 Nov 2024−20.6%
22 Nov 2024−16.4%
29 Nov 2024−13.7%
6 Dec 2024−21.4%
13 Dec 2024−18.2%
20 Dec 2024−13.3%
27 Dec 2024−12.7%
3 Jan 2025−10.0%
10 Jan 2025−10.0%
17 Jan 2025−11.4%
24 Jan 2025−14.3%
31 Jan 2025−15.0%
7 Feb 2025−4.9%
14 Feb 2025+12.8%
21 Feb 2025+13.5%
28 Feb 2025+15.7%
7 Mar 2025+26.9%
14 Mar 2025+29.0%
21 Mar 2025+24.2%
28 Mar 2025+21.9%
4 Apr 2025+17.8%
11 Apr 2025+8.0%
17 Apr 2025+12.7%
25 Apr 2025+18.7%
2 May 2025+13.7%
9 May 2025+2.9%
16 May 2025−2.0%
23 May 2025−5.8%
30 May 2025−10.2%
6 Jun 2025−15.4%
13 Jun 2025−15.8%
20 Jun 2025−17.1%
27 Jun 2025−21.9%
3 Jul 2025−22.5%
11 Jul 2025−6.9%
18 Jul 2025−9.8%
25 Jul 2025−13.4%
1 Aug 2025−11.3%
8 Aug 2025−5.6%
15 Aug 2025+4.0%
22 Aug 2025+3.5%
29 Aug 2025+3.6%
5 Sep 2025+3.9%
12 Sep 2025+4.1%
19 Sep 2025+8.4%
26 Sep 2025+13.4%
3 Oct 2025+16.6%
10 Oct 2025+15.1%
17 Oct 2025+15.4%
24 Oct 2025+13.5%
31 Oct 2025+2.0%
7 Nov 2025+5.4%
14 Nov 2025+8.0%
21 Nov 2025+10.1%
28 Nov 2025+2.3%
5 Dec 2025+0.4%
12 Dec 2025−1.4%
19 Dec 2025−0.6%
26 Dec 2025−0.1%
2 Jan 2026−4.1%
9 Jan 2026−10.8%
16 Jan 2026−10.7%
23 Jan 2026−5.6%
30 Jan 2026+0.8%
6 Feb 2026−1.0%
13 Feb 2026−1.8%
20 Feb 2026−9.5%
27 Feb 2026+1.5%
6 Mar 2026+3.7%
13 Mar 2026+1.2%
20 Mar 2026−4.9%
27 Mar 2026−0.8%
2 Apr 2026−4.9%
10 Apr 2026−3.4%
17 Apr 2026−5.5%
24 Apr 2026−13.0%
1 May 2026−11.5%
8 May 2026−16.6%
15 May 2026−17.5%
22 May 2026−12.2%
29 May 2026−16.5%
5 Jun 2026−10.9%
12 Jun 2026−8.3%
18 Jun 2026−9.6%
26 Jun 2026+6.0%
2 Jul 2026+11.4%
10 Jul 2026+8.2%
17 Jul 2026+17.5%
24 Jul 2026+27.0%
31 Jul 2026+17.8%
7 Aug 2026+17.2%
14 Aug 2026+13.5%
21 Aug 2026+20.1%
28 Aug 2026+15.6%
4 Sep 2026+8.4%
11 Sep 2026+9.9%
18 Sep 2026+19.9%
25 Sep 2026−1.5%
2 Oct 2026−2.7%
9 Oct 2026+8.3%
16 Oct 2026+9.5%
23 Oct 2026+7.3%
30 Oct 2026+16.4%
6 Nov 2026+23.3%
Each bar is one week, from 2016 to now (527 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the S&P 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 10 years the share price moved +354% while the S&P 500 moved +246%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What dividend does AbbVie pay?

AbbVie Inc. paid $6.92 per share over the last four reported quarters. The most recent declaration was $1.73 for Sep 2026. At today's price of $291.31 that is a yield of 2.38%, based on dividends already paid, not a forecast.

A dividend is cash paid out for each share. The 12-month total is the four most recent quarters added together.

Dividend per share each quarter: latest $1.73 (Sep 2026)

  • Dividend per share $1.73
Dividend per share each quarter: latest $1.73 (Sep 2026)
QuarterDividend per share
Dec 2023$1.55
Mar 2024$1.55
Jun 2024$1.55
Sep 2024$1.55
Dec 2024$1.64
Mar 2025$1.64
Jun 2025$1.64
Sep 2025$1.64
Dec 2025$1.73
Mar 2026$1.73
Jun 2026$1.73
Sep 2026$1.73
Declared dividend per share, $ a share, each reported quarter. 12 quarters on file.

Which stock lists is AbbVie on?

AbbVie is on one of our US lists: S&P 500 companies.

Is AbbVie profitable?

AbbVie Inc. earned $4.2 B of net profit in the Sep 2026 quarter, +2,289.2% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was $4.2 B. Over 4 years profit has grown −22.3% a year on average. The Sep 2026 quarter's profit is 24.2% of that quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned $176 M. 1 of the last 12 reported quarters were loss-making.

For the full year, FY25 profit was $4.2 B (−1.2% on the year before).

FY25 profit $4.2 B (−1.2% on the year before), −22.3% a year over 4 years

  • Net profit $4.2 B
FY25 profit $4.2 B (−1.2% on the year before), −22.3% a year over 4 years
QuarterNet profit
FY21$11.5 B
FY22$11.8 B
FY23$4.8 B
FY24$4.2 B
FY25$4.2 B

Growth on a year earlier

  • Growth on a year earlier −1.2%
Growth on a year earlier
QuarterGrowth on a year earlier
FY21–
FY222.7%
FY23−59.1%
FY24−12.1%
FY25−1.2%
Top: net profit each year, $ B. Below: growth on the year before, %. 5-year window. A grey bar is lower than the year before.

Sep 2026: $4.2 B (+2,289.2% on a year earlier), the 2nd quarter in a row of growth

  • Net profit (quarterly) $4.2 B
Sep 2026: $4.2 B (+2,289.2% on a year earlier), the 2nd quarter in a row of growth
QuarterNet profit (quarterly)
Dec 2023$811 M
Mar 2024$1.4 B
Jun 2024$1.4 B
Sep 2024$1.6 B
Dec 2024−$32.0 M
Mar 2025$1.3 B
Jun 2025$928 M
Sep 2025$176 M
Dec 2025$1.8 B
Mar 2026$687 M
Jun 2026$3.6 B
Sep 2026$4.2 B

Growth on a year earlier

  • Growth on a year earlier 2,289.2%
Growth on a year earlier
QuarterGrowth on a year earlier
Dec 2023−67.1%
Mar 2024496.1%
Jun 2024−32.4%
Sep 2024−12.2%
Dec 2024−103.9%
Mar 2025−6.1%
Jun 2025−31.8%
Sep 2025−88.7%
Dec 2025–
Mar 2026−46.2%
Jun 2026288.5%
Sep 20262,289.2%
Top: net profit each quarter, $ B. Below: growth on the same quarter a year earlier, %. Last 12 quarters. A grey bar is lower than the quarter before.

Why profit moved: revenue changed +10.3% on a year earlier and the margin moved +4.1 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +843.8% and revenue +10.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit.

How much revenue does AbbVie make, and is it growing?

AbbVie Inc. reported $17.4 B of revenue in the Sep 2026 quarter, +10.3% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 4 years it has grown 2.1% a year on average. The last full year, FY25, came in at $61.2 B.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $66.0 B.

FY25 revenue was $61.2 B, +8.6% on the year before.

FY25 revenue $61.2 B (+8.6% on the year before), 2.1% a year over 4 years

  • Revenue $61.2 B
FY25 revenue $61.2 B (+8.6% on the year before), 2.1% a year over 4 years
QuarterRevenue
FY21$56.2 B
FY22$58.1 B
FY23$54.3 B
FY24$56.3 B
FY25$61.2 B

Growth on a year earlier

  • Growth on a year earlier 8.6%
Growth on a year earlier
QuarterGrowth on a year earlier
FY21–
FY223.3%
FY23−6.4%
FY243.7%
FY258.6%
Top: revenue each year, $ B. Below: growth on the year before, %. 5-year window. A grey bar is lower than the year before.

Sep 2026: $17.4 B (+10.3% on a year earlier), the 11th quarter in a row of growth

  • Revenue (quarterly) $17.4 B
Sep 2026: $17.4 B (+10.3% on a year earlier), the 11th quarter in a row of growth
QuarterRevenue (quarterly)
Dec 2023$14.3 B
Mar 2024$12.3 B
Jun 2024$14.5 B
Sep 2024$14.5 B
Dec 2024$15.1 B
Mar 2025$13.3 B
Jun 2025$15.4 B
Sep 2025$15.8 B
Dec 2025$16.6 B
Mar 2026$15.0 B
Jun 2026$17.0 B
Sep 2026$17.4 B

Growth on a year earlier

  • Growth on a year earlier 10.3%
Growth on a year earlier
QuarterGrowth on a year earlier
Dec 2023−5.4%
Mar 20240.7%
Jun 20244.3%
Sep 20243.8%
Dec 20245.6%
Mar 20258.4%
Jun 20256.6%
Sep 20259.1%
Dec 202510%
Mar 202612.4%
Jun 202610.2%
Sep 202610.3%
Top: revenue each quarter, $ B. Below: growth on the same quarter a year earlier, %. Last 12 quarters. A grey bar is lower than the quarter before.

Recent pace: the last four quarters grew +10.7% on average, against 2.1% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +10.7%, against +9.0% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +338.8%, against +42.4% a year (accelerating).

How much of every $100 of sales does AbbVie keep?

AbbVie Inc.'s operating margin was 39.6% in the Sep 2026 quarter, 4.1 percentage points higher than the same quarter a year ago. Across 5 years it has been between 30.9% and 35.2%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +4.1 percentage points on the year while gross margin changed +3.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

FY25: 34.5%, within a range of 30.9% to 35.2% over 5 years

  • Operating margin 34.5%
FY25: 34.5%, within a range of 30.9% to 35.2% over 5 years
QuarterOperating margin
FY2135.2%
FY2234.8%
FY2333.5%
FY2430.9%
FY2534.5%

Change on the year before (points)

  • Change on the year before (points) +3.6 pts
Change on the year before (points)
QuarterChange on the year before (points)
FY21–
FY22−0.4 pts
FY23−1.3 pts
FY24−2.6 pts
FY25+3.6 pts
Operating margin each year, % (top). Below: change on the year before, in percentage points. 5-year window.

Sep 2026: operating margin 39.6% (+4.1 points on a year earlier)

  • Operating margin 39.6%
Sep 2026: operating margin 39.6% (+4.1 points on a year earlier)
QuarterOperating margin
Dec 202331.3%
Mar 202427.4%
Jun 202434.6%
Sep 202428.6%
Dec 202432.5%
Mar 202530.4%
Jun 202537.5%
Sep 202535.5%
Dec 202534.1%
Mar 202632.2%
Jun 202640%
Sep 202639.6%

Change on a year earlier (points)

  • Change on a year earlier (points) +4.1 pts
Change on a year earlier (points)
QuarterChange on a year earlier (points)
Dec 2023−9.1 pts
Mar 2024−2.6 pts
Jun 2024−1.0 pts
Sep 2024−4.2 pts
Dec 2024+1.2 pts
Mar 2025+3.0 pts
Jun 2025+2.9 pts
Sep 2025+6.9 pts
Dec 2025+1.6 pts
Mar 2026+1.8 pts
Jun 2026+2.5 pts
Sep 2026+4.1 pts
Top: quarterly operating margin, %. Below: change on the same quarter a year earlier, in percentage points. Last 12 quarters. Operating profit as a share of revenue, each quarter.

Is AbbVie's profit turning into cash?

Over the last 3 years, 458% of AbbVie Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $19.0 B of operating cash against $4.2 B of profit. After $1.2 B of spending on assets, $17.8 B was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

FY25: operating cash $19.0 B against profit $4.2 B; 458% of 3 years' profit came in as cash

  • Operating cash $19.0 B
  • Net profit $4.2 B
  • Free cash $17.8 B
FY25: operating cash $19.0 B against profit $4.2 B; 458% of 3 years' profit came in as cash
QuarterOperating cashNet profitFree cash
FY21$22.8 B$11.5 B$22.0 B
FY22$24.9 B$11.8 B$24.2 B
FY23$22.8 B$4.8 B$22.1 B
FY24$18.8 B$4.2 B$17.8 B
FY25$19.0 B$4.2 B$17.8 B
Operating cash flow and net profit each year, $ B. The line is free cash flow: operating cash minus spending on assets. 5-year window, yearly figures.

Sep 2026: operating cash $7.6 B = 181% of the quarter's profit

  • Operating cash (quarterly) $7.6 B
Sep 2026: operating cash $7.6 B = 181% of the quarter's profit
QuarterOperating cash (quarterly)
Dec 2023$4.8 B
Mar 2024$4.0 B
Jun 2024$2.3 B
Sep 2024$5.4 B
Dec 2024$7.0 B
Mar 2025$1.6 B
Jun 2025$5.2 B
Sep 2025$7.0 B
Dec 2025$5.2 B
Mar 2026$3.8 B
Jun 2026$3.4 B
Sep 2026$7.6 B

Operating cash as % of profit

  • Operating cash as % of profit 181%
Operating cash as % of profit
QuarterOperating cash as % of profit
Dec 2023586%
Mar 2024297%
Jun 2024167%
Sep 2024351%
Dec 2024–
Mar 2025128%
Jun 2025555%
Sep 20253,991%
Dec 2025289%
Mar 2026557%
Jun 202695%
Sep 2026181%
Top: operating cash each quarter, $ B. Below: operating cash as a % of net profit; 100% means all of the quarter's profit came in as cash. Last 12 quarters.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Where does AbbVie's cash go?

AbbVie Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $3.0 B on assets over the last 3 years. Averaged over those years that is 1.6% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $3.0 B over the last 3 years.

FY25: capex $1.2 B, steady spending

  • Capex $1.2 B
FY25: capex $1.2 B, steady spending
QuarterCapex
FY21$787 M
FY22$695 M
FY23$777 M
FY24$974 M
FY25$1.2 B
Capital spending each year, $ B.

Sep 2026: capex $301 M in the quarter

  • Capex (quarterly) $301 M
Sep 2026: capex $301 M in the quarter
QuarterCapex (quarterly)
Dec 2023$205 M
Mar 2024$193 M
Jun 2024$241 M
Sep 2024$249 M
Dec 2024$291 M
Mar 2025$235 M
Jun 2025$269 M
Sep 2025$381 M
Dec 2025$329 M
Mar 2026$265 M
Jun 2026$322 M
Sep 2026$301 M

Free cash

  • Free cash $7.3 B
Free cash
QuarterFree cash
Dec 2023$4.5 B
Mar 2024$3.8 B
Jun 2024$2.0 B
Sep 2024$5.2 B
Dec 2024$6.8 B
Mar 2025$1.4 B
Jun 2025$4.9 B
Sep 2025$6.6 B
Dec 2025$4.9 B
Mar 2026$3.6 B
Jun 2026$3.1 B
Sep 2026$7.3 B
Top: capital spending each quarter, $ B. Below: free cash flow, $ B. Last 12 quarters.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

What is AbbVie's P/E ratio, and how does it compare with its own history?

AbbVie Inc.'s P/E is 50.2×, in the middle of its own history: higher than 44% of past readings. Its usual P/E (the middle reading) is 61.1×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

P/E 50.2× against a usual 61.1×: in the middle of its own history: higher than 44% of past readings

  • P/E 50.2×
  • Median 61.1×
P/E 50.2× against a usual 61.1×: in the middle of its own history: higher than 44% of past readings
WeekP/EMedian
1 Apr 202223.3×61.1×
14 Apr 202223.3×61.1×
29 Apr 202221.0×61.1×
13 May 202222.0×61.1×
27 May 202221.5×61.1×
10 Jun 202220.5×61.1×
24 Jun 202221.8×61.1×
8 Jul 202221.6×61.1×
22 Jul 202221.0×61.1×
5 Aug 202219.5×61.1×
19 Aug 202220.1×61.1×
2 Sep 202219.3×61.1×
16 Sep 202220.4×61.1×
30 Sep 202217.9×61.1×
14 Oct 202219.1×61.1×
28 Oct 202219.7×61.1×
11 Nov 202220.0×61.1×
25 Nov 202221.3×61.1×
9 Dec 202221.7×61.1×
23 Dec 202221.8×61.1×
6 Jan 202325.1×61.1×
20 Jan 202322.6×61.1×
3 Feb 202321.9×61.1×
17 Feb 202322.8×61.1×
3 Mar 202323.6×61.1×
17 Mar 202323.3×61.1×
31 Mar 202337.6×61.1×
14 Apr 202338.2×61.1×
28 Apr 202335.7×61.1×
12 May 202334.8×61.1×
26 May 202332.5×61.1×
9 Jun 202332.6×61.1×
23 Jun 202332.1×61.1×
7 Jul 202327.9×61.1×
21 Jul 202329.6×61.1×
4 Aug 202330.4×61.1×
18 Aug 202330.9×61.1×
1 Sep 202330.5×61.1×
15 Sep 202331.3×61.1×
29 Sep 202330.6×61.1×
13 Oct 202340.5×61.1×
27 Oct 202338.0×61.1×
10 Nov 202337.9×61.1×
24 Nov 202338.0×61.1×
8 Dec 202340.9×61.1×
22 Dec 202342.4×61.1×
5 Jan 202459.5×61.1×
19 Jan 202460.4×61.1×
2 Feb 202461.9×61.1×
16 Feb 202465.1×61.1×
1 Mar 202465.6×61.1×
15 Mar 202465.3×61.1×
28 Mar 202466.8×61.1×
12 Apr 202448.2×61.1×
26 Apr 202447.4×61.1×
10 May 202447.8×61.1×
24 May 202446.7×61.1×
7 Jun 202450.4×61.1×
21 Jun 202450.6×61.1×
5 Jul 202455.8×61.1×
19 Jul 202457.5×61.1×
2 Aug 202463.2×61.1×
16 Aug 202464.7×61.1×
30 Aug 202465.5×61.1×
13 Sep 202464.8×61.1×
27 Sep 202465.0×61.1×
11 Oct 202467.6×61.1×
25 Oct 202465.4×61.1×
8 Nov 202469.5×61.1×
22 Nov 202461.6×61.1×
6 Dec 202461.4×61.1×
20 Dec 202461.1×61.1×
3 Jan 202575.6×61.1×
17 Jan 202571.6×61.1×
31 Jan 202576.8×61.1×
14 Feb 202580.5×61.1×
28 Feb 202587.2×61.1×
14 Mar 202588.4×61.1×
28 Mar 202585.7×61.1×
11 Apr 202574.6×61.1×
25 Apr 202579.3×61.1×
9 May 202578.7×61.1×
23 May 202578.1×61.1×
6 Jun 202580.9×61.1×
20 Jun 202579.0×61.1×
3 Jul 202590.2×61.1×
18 Jul 202590.2×61.1×
1 Aug 202593.0×61.1×
15 Aug 202598.5×61.1×
29 Aug 2025100.3×61.1×
12 Sep 2025104.1×61.1×
26 Sep 2025105.2×61.1×
10 Oct 2025174.1×61.1×
24 Oct 2025172.6×61.1×
7 Nov 2025165.9×61.1×
21 Nov 2025174.1×61.1×
5 Dec 2025171.1×61.1×
19 Dec 2025171.7×61.1×
2 Jan 202697.3×61.1×
16 Jan 202690.9×61.1×
30 Jan 202694.6×61.1×
13 Feb 202698.2×61.1×
27 Feb 202698.4×61.1×
13 Mar 202693.2×61.1×
27 Mar 202688.8×61.1×
10 Apr 2026102.6×61.1×
24 Apr 202698.1×61.1×
8 May 202699.5×61.1×
22 May 2026106.5×61.1×
5 Jun 2026112.2×61.1×
18 Jun 2026106.9×61.1×
2 Jul 202673.8×61.1×
17 Jul 202672.0×61.1×
31 Jul 202671.0×61.1×
14 Aug 202670.6×61.1×
28 Aug 202672.3×61.1×
11 Sep 202672.7×61.1×
25 Sep 202674.8×61.1×
9 Oct 202647.6×61.1×
23 Oct 202649.2×61.1×
6 Nov 202650.2×61.1×

Earnings per share, 12 months

  • Earnings per share, 12 months $5.80
Earnings per share, 12 months
WeekEarnings per share, 12 months
1 Apr 2022–
14 Apr 2022–
29 Apr 2022–
13 May 2022–
27 May 2022–
10 Jun 2022–
24 Jun 2022$6.98
8 Jul 2022$6.98
22 Jul 2022$6.98
5 Aug 2022$6.98
19 Aug 2022$6.98
2 Sep 2022$6.98
16 Sep 2022$6.98
30 Sep 2022$7.50
14 Oct 2022$7.50
28 Oct 2022$7.50
11 Nov 2022$7.50
25 Nov 2022$7.50
9 Dec 2022$7.50
23 Dec 2022$7.50
6 Jan 2023$7.50
20 Jan 2023$7.50
3 Feb 2023$7.50
17 Feb 2023$7.50
3 Mar 2023$7.50
17 Mar 2023$7.50
31 Mar 2023$4.23
14 Apr 2023$4.23
28 Apr 2023$4.23
12 May 2023$4.23
26 May 2023$4.23
9 Jun 2023$4.23
23 Jun 2023$4.86
7 Jul 2023$4.86
21 Jul 2023$4.86
4 Aug 2023$4.86
18 Aug 2023$4.86
1 Sep 2023$4.86
15 Sep 2023$4.86
29 Sep 2023$4.86
13 Oct 2023$4.86
27 Oct 2023$4.86
10 Nov 2023$4.86
24 Nov 2023$4.86
8 Dec 2023$4.86
22 Dec 2023$4.86
5 Jan 2024$3.65
19 Jan 2024$3.65
2 Feb 2024$3.65
16 Feb 2024$3.65
1 Mar 2024$3.65
15 Mar 2024$3.65
28 Mar 2024$2.73
12 Apr 2024$2.73
26 Apr 2024$2.73
10 May 2024$2.73
24 May 2024$2.73
7 Jun 2024$2.73
21 Jun 2024$3.37
5 Jul 2024$3.37
19 Jul 2024$3.37
2 Aug 2024$3.37
16 Aug 2024$3.37
30 Aug 2024$3.37
13 Sep 2024$3.37
27 Sep 2024$3.00
11 Oct 2024$3.00
25 Oct 2024$3.00
8 Nov 2024$3.00
22 Nov 2024$3.00
6 Dec 2024$3.00
20 Dec 2024$3.00
3 Jan 2025$2.87
17 Jan 2025$2.87
31 Jan 2025$2.87
14 Feb 2025$2.87
28 Feb 2025$2.87
14 Mar 2025$2.87
28 Mar 2025$2.40
11 Apr 2025$2.40
25 Apr 2025$2.40
9 May 2025$2.40
23 May 2025$2.40
6 Jun 2025$2.40
20 Jun 2025$2.40
3 Jul 2025$2.35
18 Jul 2025$2.35
1 Aug 2025$2.35
15 Aug 2025$2.35
29 Aug 2025$2.35
12 Sep 2025$2.35
26 Sep 2025$2.10
10 Oct 2025$2.10
24 Oct 2025$2.10
7 Nov 2025$2.10
21 Nov 2025$2.10
5 Dec 2025$2.10
19 Dec 2025$2.10
2 Jan 2026$1.32
16 Jan 2026$1.32
30 Jan 2026$1.32
13 Feb 2026$1.32
27 Feb 2026$1.32
13 Mar 2026$1.32
27 Mar 2026$2.36
10 Apr 2026$2.36
24 Apr 2026$2.36
8 May 2026$2.36
22 May 2026$2.36
5 Jun 2026$2.36
18 Jun 2026$2.36
2 Jul 2026$2.03
17 Jul 2026$2.03
31 Jul 2026$2.03
14 Aug 2026$2.03
28 Aug 2026$2.03
11 Sep 2026$2.03
25 Sep 2026$3.54
9 Oct 2026$3.54
23 Oct 2026$3.54
6 Nov 2026$5.80
Top: P/E each week. Below: earnings per share, trailing twelve months, a step line that moves once a quarter; 4.6 years of history; short peaks above 174× are drawn at the top edge.
50.2×P/E · lower than 56% of its last 4.6 years
1.36PEG · today, as reported

Why the multiple is where it is: over the past year earnings per share moved −1.3% while the price moved +32.9%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 3 years the price moved +27.2% a year; about +16.7% a year came from earnings growth and about +10.5 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

Is the AbbVie business getting better or worse?

AbbVie Inc.'s business is giving mixed signals. There is no clear direction across the growth lines; each line tells part of the story. This is based on 12 quarters of 3 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Growth year by year: revenue +8.6% in FY25, profit −1.2%

  • Revenue growth 8.6%
Growth year by year: revenue +8.6% in FY25, profit −1.2%
QuarterRevenue growth
FY21–
FY223.3%
FY23−6.4%
FY243.7%
FY258.6%

Profit growth, EPS growth

  • Profit growth −1.2%
  • EPS growth −1.3%
Profit growth, EPS growth
QuarterProfit growthEPS growth
FY21––
FY222.7%2.8%
FY23−59.1%−59%
FY24−12.1%−12.1%
FY25−1.2%−1.3%
Growth on the year before, each year, %. Top: revenue. Below: net profit and earnings per share, on their own scale because profit growth swings much more. Zero line drawn.

Three growth lines over twelve quarters: revenue stabilising, profit accelerating

  • Revenue 10.7%
Three growth lines over twelve quarters: revenue stabilising, profit accelerating
QuarterRevenue
Dec 2023−6.4%
Mar 2024−4.1%
Jun 2024−1.8%
Sep 20240.7%
Dec 20243.7%
Mar 20255.4%
Jun 20256.1%
Sep 20257.4%
Dec 20258.6%
Mar 20269.5%
Jun 202610.4%
Sep 202610.7%

Profit, EPS

  • Profit 300%
  • EPS 300%
Profit, EPS
QuarterProfitEPS
Dec 2023−59.1%−58.8%
Mar 2024−21%−20.5%
Jun 2024−38.6%−38.4%
Sep 2024−21.5%−21.4%
Dec 2024−12.1%−12.1%
Mar 2025−30.2%−30.2%
Jun 2025−29.7%−30%
Sep 2025−53.8%−54%
Dec 2025−1.2%−1.6%
Mar 2026−13.4%−13.7%
Jun 202668.5%68.5%
Sep 2026300%300%
Growth on a year earlier, % at each quarter end. Top: revenue. Below: profit and earnings per share, on their own scale because they swing much more. Each is measured over the last 12 months. Extreme jumps from a tiny base are drawn at the edge (▲). A gap means there is no reading for that quarter.
Steady highRevenue growth · latest (Sep 2026) +10.7%, range −6.4% to +10.7%
FlatProfit growth · latest (Sep 2026) +338.8%, range −59.1% to +338.8%
FlatEPS growth · latest (Sep 2026) +339.5%, range −58.8% to +339.5%

Why it matters: when the lines disagree, each line above matters more than any single label.

The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading.

The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+8.6%+1.8%——
Profit−1.2%−29.2%——
EPS−1.3%−29.1%——
Stock price+32.9%+27.2%+20.0%+17.9%
+10.3%Revenue growth (Sep 2026) · latest quarter against a year ago
+2,289.2%Profit growth (Sep 2026) · latest quarter against a year ago
2.1%Revenue, 4 years · yearly growth over the long run

How much does AbbVie earn on its capital?

AbbVie Inc. earned a ROE of −130% in FY25. Its return on capital used (ROIC) is 14.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 6.8% net margin and 0.46× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 6.8% net margin × 0.46× asset turnover × −41.50× leverage (assets divided by equity) ≈ −129.8% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 19.7% − 5.0% = +14.7 percentage points. The 5.0% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

The 19.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 17.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

FY25: ROE −130%, the full history

  • ROE −129.7%
  • ROIC (annual) 17.3%
  • Cost of capital 5%
FY25: ROE −130%, the full history
QuarterROEROIC (annual)Cost of capital
FY2174.3%20.1%5%
FY2268.2%22.8%5%
FY2346.4%21.7%5%
FY24126%28.1%5%
FY25−129.7%17.3%5%
Return on equity each year, % (line); ROIC each year, % (line). 5-year window, low years included. The flat line is the 5.0% cost of capital used on this page.

Sep 2026: ROIC 18.9% (last 12 months) against a 5.0% cost of capital

  • ROIC (12 months) 18.9%
  • ROE (12 months) 6,225%
  • Cost of capital 5.0%
Sep 2026: ROIC 18.9% (last 12 months) against a 5.0% cost of capital
QuarterROIC (12 months)ROE (12 months)Cost of capital
Dec 202319.7%35.2%5%
Mar 202420.5%56.2%5%
Jun 202420.1%54.3%5%
Sep 202418.4%56.4%5%
Dec 202422.3%62.3%5%
Mar 202522%88.4%5%
Jun 202518.1%112.9%5%
Sep 202515.8%138%5%
Dec 202515.3%6,225%5%
Mar 202615%–5%
Jun 202615%–5%
Sep 202618.9%–5%
ROIC and ROE over the last 12 months, each quarter, %; the flat line is the cost of capital. Last 12 quarters, lined up with the yearly figure.

Does AbbVie have too much debt?

AbbVie Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 5.03 in FY21 to −21.19 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

FY25: debt $68.4 B, −21.19× equity

  • Total debt $68.4 B
FY25: debt $68.4 B, −21.19× equity
QuarterTotal debt
FY21$77.6 B
FY22$64.6 B
FY23$60.6 B
FY24$68.3 B
FY25$68.4 B

Debt-to-equity

  • Debt-to-equity −21.2×
Debt-to-equity
QuarterDebt-to-equity
FY215.03×
FY223.74×
FY235.83×
FY2420.3×
FY25−21.2×
Top: total debt each year, $ B. Below: debt-to-equity, ×. 5-year window.

Sep 2026: debt $81.3 B, debt-to-equity −17.92

  • Total debt (quarterly) $81.3 B
Sep 2026: debt $81.3 B, debt-to-equity −17.92
QuarterTotal debt (quarterly)
Dec 2023$60.6 B
Mar 2024$74.4 B
Jun 2024$70.9 B
Sep 2024$71.3 B
Dec 2024$68.3 B
Mar 2025$70.0 B
Jun 2025$70.6 B
Sep 2025$68.8 B
Dec 2025$68.4 B
Mar 2026$72.9 B
Jun 2026$70.9 B
Sep 2026$81.3 B

Debt-to-equity

  • Debt-to-equity −17.9×
Debt-to-equity
QuarterDebt-to-equity
Dec 20235.83×
Mar 20249.24×
Jun 202410.4×
Sep 202411.8×
Dec 202420.3×
Mar 202547.9×
Jun 2025−511.5×
Sep 2025−26.5×
Dec 2025−21.2×
Mar 2026−11.0×
Jun 2026−12.0×
Sep 2026−17.9×
Top: total debt each quarter, $ B. Below: debt-to-equity, ×. Last 12 quarters.

What is the AbbVie shareholding pattern?

0.9% of AbbVie Inc.'s tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 3.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

0.9%Short interest · of the tradable float
3.2Days to cover · at typical volumes

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

How far is AbbVie from balance-sheet trouble?

For AbbVie Inc., the Z-score is 2.39. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 2.39 is in the grey area, neither clearly safe nor clearly in trouble.

How does AbbVie rank in its industry?

65.9 out of 100, rank 2 of 13 in Drug Manufacturers - General, with 65% of the evidence available.

AbbVie Inc. scores 65.9 out of 100 against the 13 companies it is compared with in Drug Manufacturers - General, ranking 2. There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.

The three scored parts add up to the total exactly: 34.8 + 23.6 + 7.5 = 65.9 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is AbbVie compared with?

AbbVie ranks 2 of 13 Drug Manufacturers - General companies on the 4-Factor Sector Score, with 65.9 out of 100.

  1. 1Eli Lilly and CompanyLLY · turning · Sector-leading setup · 65% evidence85.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 40.5/43.75 · Revenue 45.5% · Profit 49.8% · Operating margin change 6.1 points · 95% evidenceCapital efficiency 26.3/31.25 · ROCE 43.5% · Operating margin 53.7% · 76% evidenceValuation 18.4/25 · P/E 37.4× · PEG 0.48 · 65% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 40.5 + 26.3 + 18.4 = 85.2 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  2. 2AbbVie Inc. this pageABBV · breaking out · Most evidence points up · 65% evidence65.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 34.8/43.75 · Revenue 10.7% · Profit 100% · Operating margin change 4.1 points · 95% evidenceCapital efficiency 23.6/31.25 · ROCE 23.1% · Operating margin 39.6% · 76% evidenceValuation 7.5/25 · P/E 50.2× · PEG 1.36 · 65% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 34.8 + 23.6 + 7.5 = 65.9 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  3. 3Bristol-Myers Squibb CompanyBMY · turning · Evidence leans up · 65% evidence61.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 29.8/43.75 · Revenue 4.2% · Profit 53.1% · Operating margin change 2.2 points · 95% evidenceCapital efficiency 22.8/31.25 · ROCE 23.1% · Operating margin 33.8% · 76% evidenceValuation 8.8/25 · P/E 13.8× · PEG 3 · 65% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 29.8 + 22.8 + 8.8 = 61.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  4. 4AstraZeneca PLCAZN · turning · Evidence leans up · 65% evidence59.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 25.9/43.75 · Revenue 7.3% · Profit 17.4% · Operating margin change 6 points · 95% evidenceCapital efficiency 15.8/31.25 · ROCE 18.1% · Operating margin 29.6% · 76% evidenceValuation 17.3/25 · P/E 22.9× · PEG 1 · 65% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 25.9 + 15.8 + 17.3 = 59 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  5. 5Gilead Sciences, Inc.GILD · leader · Too little evidence to rank firmly · 55% evidence56.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 18.0/43.75 · Revenue 6.5% · Profit -147.6% · Operating margin change -2.8 points · 95% evidenceCapital efficiency 23.8/31.25 · ROCE 30.1% · Operating margin 42.4% · 76% evidenceValuation 14.4/25 · P/E -47.8× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 18 + 23.8 + 14.4 = 56.2 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  6. 6Amgen Inc.AMGN · leader · Evidence leans up · 65% evidence54.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 30.1/43.75 · Revenue 8.2% · Profit 34.1% · Operating margin change 1.6 points · 95% evidenceCapital efficiency 17.3/31.25 · ROCE 18.1% · Operating margin 35.8% · 76% evidenceValuation 6.6/25 · P/E 24.3× · PEG 3.42 · 65% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 30.1 + 17.3 + 6.6 = 54 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  7. 7Novartis AGNVS · turning · Evidence leans up · 65% evidence50.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 16.0/43.75 · Revenue 1.8% · Profit -30.4% · Operating margin change 3.4 points · 95% evidenceCapital efficiency 22.8/31.25 · ROCE 21.6% · Operating margin 34.3% · 76% evidenceValuation 11.2/25 · P/E 27.2× · PEG 2.27 · 65% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 16 + 22.8 + 11.2 = 50 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  8. 8GSK plcGSK · quiet · Too little evidence to rank firmly · 55% evidence48.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 13.7/43.75 · Revenue 4.3% · Profit -20.5% · Operating margin change -4 points · 95% evidenceCapital efficiency 20.5/31.25 · ROCE 19.3% · Operating margin 32.1% · 76% evidenceValuation 13.8/25 · P/E 16.9× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 13.7 + 20.5 + 13.8 = 48 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  9. 9Johnson & JohnsonJNJ · turning · Too little evidence to rank firmly · 55% evidence45.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 17.0/43.75 · Revenue 7.8% · Profit -35.9% · Operating margin change -4.5 points · 95% evidenceCapital efficiency 16.8/31.25 · ROCE 18.6% · Operating margin 25.7% · 76% evidenceValuation 11.3/25 · P/E 40.6× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 17 + 16.8 + 11.3 = 45.1 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  10. 10Merck & Co., Inc.MRK · leader · Too little evidence to rank firmly · 55% evidence36.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 9.3/43.75 · Revenue 4.9% · Profit -87.1% · Operating margin change 0.4 points · 95% evidenceCapital efficiency 16.5/31.25 · ROCE 18.3% · Operating margin 41.2% · 76% evidenceValuation 10.6/25 · P/E 146.1× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 9.3 + 16.5 + 10.6 = 36.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  11. 11Pfizer Inc.PFE · leader · Too little evidence to rank firmly · 55% evidence32.4out of 100GrowthCapitalValuationRelative
  12. 12Biogen Inc.BIIB · breaking out · Too little evidence to rank firmly · 55% evidence25.4out of 100GrowthCapitalValuationRelative
  13. 13SanofiSNY · turning · Too little evidence to rank firmly · 38% evidence51.4out of 100GrowthCapitalValuationRelative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Drug Manufacturers - General, all 13 compared on one page.

Which companies are close to AbbVie in size?

AbbVie is the 3rd largest of 14 Drug Manufacturers - General companies on Sector Alpha by market value (scores of 12 November 2026). Just above it: Eli Lilly and Company and Johnson & Johnson. Just below it: Merck & Co., Inc., Novartis AG, AstraZeneca PLC and Amgen Inc.

Drug Manufacturers - General companies close in size

  1. Eli Lilly and Company $1.21 trillion
  2. Johnson & Johnson $664.9 billion
  3. AbbVie Inc. $514.9 billion
  4. Merck & Co., Inc. $361.7 billion
  5. Novartis AG $306.6 billion
  6. AstraZeneca PLC $288.8 billion
  7. Amgen Inc. $249 billion

All 14 Drug Manufacturers - General companies, largest first

Companies close in size in other industries

  1. Mastercard Incorporated $568.6 billion · Credit Services
  2. ASML Holding N.V. $547.3 billion · Semiconductor Equipment & Materials
  3. AbbVie Inc. $514.9 billion
  4. Costco Wholesale Corporation $466.9 billion · Discount Stores
  5. Chevron Corporation $414.9 billion · Oil & Gas Integrated

What else do people ask about AbbVie?

What is AbbVie's stock price today?

AbbVie Inc.'s stock price is $291.31, +32.9% over the past year. The whole company is worth $515 B on the market.

In the last 52 weeks it traded between $199 to $295; today it is 96% of the way up from the low, 21.9% above its 200-day average (as of 6 November 2026).

What were AbbVie's latest quarterly results?

AbbVie Inc. reported revenue of $17.4 B and net profit of $4.2 B for the Sep 2026 quarter. Revenue rose 10.3% and profit rose 2,289.2% compared with a year earlier. Earnings per share were $2.37.

The operating margin was 39.6%, 4.1 percentage points higher than a year earlier (as of 6 November 2026).

What is AbbVie's market cap?

AbbVie Inc.'s market capitalisation is $515 B at a stock price of $291.31. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 6 November 2026).

How is AbbVie performing?

AbbVie Inc.'s share price has been rising for 20 weeks. In its latest quarter, revenue rose 10.3% and profit rose 2,289.2% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 5 weeks running (as of 6 November 2026).

Will AbbVie's stock price go up?

This page does not forecast AbbVie Inc.'s stock price. What it shows instead: the stock price is $291.31, and it has been rising for 20 weeks. Its P/E of 50.2× is higher than 44% of its own last 5 years (as of 6 November 2026).

Where is AbbVie in its business cycle?

AbbVie Inc.'s FY25 operating margin was 34.5%, against a 5-year range of 30.9% to 35.2%. The latest quarter was 39.6%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 6 November 2026).

What could break the AbbVie story?

The main question: the share price moved +32.9% in a year while yearly earnings per share moved −1.3%. The difference came from the market paying a higher multiple.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 6 November 2026).

Is AbbVie a stock worth studying right now?

What the numbers show: AbbVie Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers.

The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 6 November 2026).

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 6 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.